Skip to main content
Clinical Trials/NCT04359004
NCT04359004
Completed
N/A

A Study to Evaluate the Effect of Vagus Nerve Stimulation in Patients Undergoing Ventricular Tachycardia (VT) Ablation

University of California, Los Angeles1 site in 1 country5 target enrollmentDecember 8, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Arrhythmia
Sponsor
University of California, Los Angeles
Enrollment
5
Locations
1
Primary Endpoint
The change in ventricular action potential duration during stimulation compared to baseline in msec
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Vagus nerve stimulation (VNS) has been shown to be beneficial in multiple studies including heart failure. The goal of this clinical investigation is to gain additional information about how vagus nerve stimulation relates to abnormal heart rhythms. The outcomes of this study will help researchers design new therapies for patients that have complex and life-threatening ventricular arrhythmias.

Detailed Description

This study is a non-randomized, prospective study in 6 patients with scar mediated ventricular arrhythmias who are scheduled to undergo a catheter ablation procedure. The study will last up to 30 minutes in the cardiac electrophysiology lab. Cervical VNS is performed percutaneously through the internal jugular vein during the patient's routine ventricular tachycardia (VT) ablation procedure.

Registry
clinicaltrials.gov
Start Date
December 8, 2020
End Date
October 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kalyanam Shivkumar, MD, PhD

Director, UCLA Cardiac Arrhythmia Center & EP Programs

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

  • Presence of structural heart disease as defined as EF ≤ 50% or presence of ventricular scar as detected by imaging modalities or electroanatomic mapping, hypertrophic cardiomyopathy, cardiac sarcoidosis, or arrhythmogenic right ventricular cardiomyopathy.
  • Age \> 18 years old
  • Underlying sinus rhythm with heart rate \> 50 bpm.
  • Provision of signed/dated informed consent and stated willingness to comply with all study procedures

Exclusion Criteria

  • Active ongoing cardiac ischemia as assessed by: ECG, cardiac enzymes, symptoms, coronary angiography with evidence of significant epicardial coronary stenosis (\>70%), or stress testing. (Note: positive troponin assay due to Internal Cardiac Defibrillator (ICD) shocks is not an exclusion criterion).
  • Status post orthotopic heart transplantation
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal).
  • Unable or unwilling to comply with protocol requirements.
  • Known channelopathy such as long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic VT.
  • Known peripheral neuropathy or history of autonomic dysfunction due to non-cardiac causes.
  • New York Heart Association Class IV heart failure or use of current vasopressor medications
  • Incessant VT
  • Persistent atrial fibrillation
  • Frequent premature atrial or ventricular contractions

Outcomes

Primary Outcomes

The change in ventricular action potential duration during stimulation compared to baseline in msec

Time Frame: Up to 30 minutes or completion of the vagus nerve stimulation

Secondary Outcomes

  • The change in blood pressure during stimulation compared to baseline in mmHg.(Up to 30 minutes or completion of the vagus nerve stimulation)
  • The change in heart rate during stimulation compared to baseline in beats per minute(Up to 30 minutes or completion of the vagus nerve stimulation)

Study Sites (1)

Loading locations...

Similar Trials